The clinical trial (NCT02541370) conducted by Dai H, et al. focuses on the treatment of advanced solid tumors (hepatocellular carcinoma, pancreatic carcinoma, etc.)with CD133 CAR-T cells. This evidence concerns the gene PROM1 and hepatocellular carcinoma.